CI

At a glance

ClinicalIndex Comparison Record
Phase 1Unknown· 50 target
Drug / intervention
HY-0102drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06094777
NCT06094777Phase 1Unknown
CompareCT.gov

A Phase 1, Multicenter, Open-label, Dose-escalation and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumors

Shanghai YingLi Pharmaceutical Co. Ltd.·interventional·Posted Oct 23, 2023·Updated Jun 13, 2024

In Brief

A Phase 1 clinical trial evaluating HY-0102 for Advanced Solid Tumor. Targeting 50 participants across 1 site.

Detailed Summary

This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of HY-0102 administered intravenously (IV) once every two weeks in patients with advanced solid tumors, so as to confirm the recommended phase 2 dose of HY-0102 and obtain the preliminary efficacy information of patients with advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--

Timeline

Phase 1UnknownOverdue
202420252026
First PostedOct 23, 2023
Enrollment StartDec 18, 2023
Primary CompletionJun 1, 2025
Study CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 2.7 years ago

Interventions

HY-0102drug

Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle